Helix Biopharma Awarded First U.S. Patent for DOS47

[dadstimeon]

http://www.pharmalive.com/News/index.cf ... egoryid=32

Aurora, Ontario– May 3, 2007,Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864) announced today the issuance of a patent (U.S. Patent No. 7,211,250) from the United States Patent & Trademark Office relating to the method and composition in combining DOS47 with targeting agents in the treatment of cancer. Helix is currently developing its first DOS47-based cancer therapeutic, L-DOS47, a drug product candidate for the treatment of adenocarcinoma of the lung.

“This patent provides Helix with significant intellectual property protection and is a vital step toward our goal of bringing DOS47-based cancer therapeutics to market,” said Donald H. Segal, President and CEO of Helix. “We will continue to advance our worldwide DOS47 patent strategy in support of the development of L-DOS47 with a view to maximizing the commercial opportunity of this product and future products derived from our DOS47 technology platform."

Preliminary in vitro and in vivo testing of L-DOS47 has been completed with certain research findings presented in peer-reviewed publications, posters and scientific meetings. See our website at www.helixbiopharma.com for further information on these publications, posters and meetings. In addition, Helix has begun scale-up manufacturing of L-DOS47 for the Company’s upcoming preclinical and clinical

testing initiatives.

“Though we are focused on L-DOS47 as our first DOS47-based cancer therapeutic, we continue to explore other cancer-specific targeting agents with the goal of developing a portfolio of conjugated DOS47-based cancer therapeutics,” commented Dr. Heman Chao, Helix’s Vice President of Research.

About L-DOS47

L-DOS47 combines Helix’s proprietary DOS47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its Topical Interferon Alpha- 2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the Toronto Stock Exchange under the ticker symbol “HBP”.

For further information contact:

Investor Relations Media Relations

Christina Bessant Matthew Haines

The Equicom Group Inc. Russo Partners LLC

Tel: (416) 815-0700 ext. 269 Tel: (212) 845-4235

(800) 385-5451 Fax: (212) 845-4260

Fax: (416) 815-0080 Email: matthew.haines@russopartnersllc.com

Email: cbessant@equicomgroup.com www.russopartnersllc.com

3-305 Industrial Parkway South

Aurora, Ontario, Canada, L4G 6X7

Phone: (905) 841-2300

Fax: (905) 841-2244

Web: www.helixbiopharma.com